The Broad will now offer licenses for both its own CRISPR IP and MilliporeSigma's to companies using CRISPR in their research and development activities.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
